Trial site
Sarah Cannon Research Institute
- 93running trials
- 61closed trials
The trials here
What the 154 trials at this site are about, from their registry records.
- Conditions
- Lung cancer63 trials
- Colorectal cancer30 trials
- Melanoma26 trials
- Ovarian cancer23 trials
- Gastric and oesophageal cancer22 trials
- Head and neck cancer22 trials
- Pancreatic cancer20 trials
- Bladder cancer19 trials
- Prostate cancer18 trials
- Endometrial cancer16 trials
- Triple-negative breast cancer14 trials
- Metastatic breast cancer11 trials
- and 21 more
- Phase
- Phase 162 trials
- Phase 1/238 trials
- Phase 230 trials
- Phase 317 trials
- Phase 2/33 trials
- Phase 41 trial
- Status
- Active, not recruiting47 trials
- Recruiting45 trials
- Completed37 trials
- Terminated20 trials
- Withdrawn4 trials
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company9 trials
- Janssen Research & Development, LLC8 trials
- Amgen7 trials
- Daiichi Sankyo6 trials
- Novartis Pharmaceuticals6 trials
- and 85 more
Running trials
Recruiting
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Recruiting
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Recruiting
Recruiting
Recruiting
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Recruiting
Recruiting
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Recruiting
Recruiting
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Recruiting
Recruiting
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Recruiting
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Active, not recruiting
Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
Active, not recruiting
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Recruiting
Recruiting
Active, not recruiting
Recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Active, not recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Active, not recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Active, not recruiting
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Recruiting
Recruiting
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Recruiting
Recruiting
Recruiting
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Active, not recruiting
Active, not recruiting
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Showing 50 of 93.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer16 recruiting
- Bladder cancer8 recruiting
- Pancreatic cancer8 recruiting
- Prostate cancer8 recruiting
- Endometrial cancer7 recruiting
- Melanoma7 recruiting
- Ovarian cancer7 recruiting
- Colorectal cancer6 recruiting
- Gastric and oesophageal cancer6 recruiting
- Head and neck cancer5 recruiting
- Metastatic breast cancer5 recruiting
- Cervical cancer4 recruiting
- Childhood cancers4 recruiting
- Liver and biliary tract cancer4 recruiting
- Kidney cancer3 recruiting
- Multiple myeloma3 recruiting
- Triple-negative breast cancer3 recruiting
- Diffuse large B-cell lymphoma2 recruiting
- Follicular lymphoma2 recruiting
- Mesothelioma2 recruiting
- Sarcoma2 recruiting
- Acute myeloid leukaemia1 recruiting
- Hodgkin lymphoma1 recruiting
- Myelodysplastic syndromes1 recruiting
- Thyroid cancer1 recruiting
Closed trials
Terminated
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Terminated
Withdrawn
Terminated
Withdrawn
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Terminated
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Withdrawn
Terminated
Completed
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
Completed
Recruiting
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Completed
Terminated
Completed
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Terminated
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Completed
Terminated
Terminated
Terminated
Terminated
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Terminated
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Terminated
Completed
Terminated
Completed
Completed
Completed
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Completed
Completed
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
Completed
Completed
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Terminated
Completed
Terminated
Completed
Completed
Completed
Completed
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Completed
Completed
Completed
Completed
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Completed
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Completed
Recruiting
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Completed
Completed
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Completed
Showing 50 of 61.
Site data: ClinicalTrials.govUpdated 17 Nov 2026